Filing Flows › Comparisons › OBIO vs PAVM
Orchestra BioMed Holdings vs PAVmed: OBIO and PAVM compared
Orchestra BioMed Holdings is the larger company: $88K of revenue in its latest quarter (Q2 2026) against $33K for PAVmed (Q2 2026). PAVmed is growing faster (+450% against -90% a year earlier).
Where the money goes: OBIO and PAVM
Orchestra BioMed Holdings (OBIO) · Q2 2026
Orchestra BioMed Holdings, Q2 2026: revenue $88K (-90% year over year), net loss $23.8M, operating cash flow −$19.3M. The chart follows the revenue to costs, profit and cash.
PAVmed (PAVM) · Q2 2026
PAVmed, Q2 2026: revenue $33K (+450% year over year), net loss $6.6M, operating cash flow −$2.7M. The chart follows the revenue to costs, profit and cash.
| Orchestra BioMed Holdings (OBIO) | PAVmed (PAVM) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $88K | $33K |
| Revenue growth, Y/Y | -90% | +450% |
| Operating margin | n/m | n/m |
| Net earnings | −$23.8M | −$6.6M |
| Operating cash flow | −$19.3M | −$2.7M |
Questions
Which is bigger, Orchestra BioMed Holdings or PAVmed?
Orchestra BioMed Holdings is the larger company: $88K of revenue in its latest quarter (Q2 2026) against $33K for PAVmed (Q2 2026).
Is Orchestra BioMed Holdings or PAVmed growing faster?
PAVmed is growing faster (+450% against -90% a year earlier).
More: Orchestra BioMed Holdings earnings · how Orchestra BioMed Holdings makes money · PAVmed earnings · how PAVmed makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 10, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.